Breast Cancer Experts Celebrate the News of KEYNOTE-522
KEYNOTE-522 Delivers Major Advance for TNBC Patients
Researchers discuss the need for biomarkers to tailor treatment options for better quality of life for patients
Total Impressions 143,697
Sentiment Analysis
| Doctor Name |
Sentiment |
Comment |
|
Naoto T Ueno, MD, PhD |
POSITIVE
|
Fantastic. But I still believe there is a fraction of people who do not benefit immunotherapy. We need a biomarker driven approach. #ASCO24 #Oncoalert https://t.co/aqpwcmbxC4 |
|
Toni Choueiri, MD |
POSITIVE
|
OS with IO on the perioperative setting in breast cancer —big news ! @stolaney1 @OncoAlert @DFCI_BreastOnc https://t.co/43xGV29fvV |
|
Evandro de Azambuja, MD, PhD |
POSITIVE
|
Important Overall Survival results in KEYNOTE-522. Important advance for our patients with #early TNBC, but we are still waiting biomarker analyses for this trial... @FDAOncology @OncoAlert @Merck #bcsm #research https://t.co/bqIp15jGg7 |
|
Jame Abraham, MD, FACP |
POSITIVE
|
Overall survival improvement with Immunotherapy in neoadjuvant- triple negative breast cancer ! KEYNOTE 522 https://t.co/WceiHaHD7d |
|
Erika Hamilton, MD |
POSITIVE
|
This is really important and so encouraging to see. Especially in #HER-2 and #TNBC, it's clear DDFS is a surrogate for OS. Now we have to figure if we can give immunotherapy with less chemo than KN522. This can be a tough regimen for many. #bcsm https://t.co/GOjfQVplF8 |
|
Sara Tolaney |
POSITIVE
|
very important news! Overall Survival seen in KN522!!! https://t.co/YmwsCohjno |
|
Noelle Girard |
POSITIVE
|
@ErikaHamilton9 Excellent results from KEYNOTE-522! Critical to now review the full data to potentially reduce chemo burden in treatment plans. #BreastCancer #TNBC |
|
Elad Sharon |
POSITIVE
|
Overall survival advantage for the use of pembrolizumab in breast cancer from the Keynote-522 trial. Exciting to see this key secondary endpoint reported! https://t.co/2loDIZeIS9 |
|
Elisa Agostinetto |
POSITIVE
|
Today’s press release by Merck: KEYNOTE-522 met its overall survival endpoint in high-risk early TNBC Excellent news for our #breastcancer patients @OncoAlert https://t.co/S1SK9yeggW |
|
Toni Choueiri, MD |
POSITIVE
|
KEYNOTE-522 shows that the addition of neoadjuvant + adjuvant #pembro to neoadjuvant chemo leads to a significant and meaningful improvement in OS [HR, 0.66 (0.95% CI, 0.50-0.87); P=0.0015] in pts w/ high-risk early-stage #TNBC! @myESMO #ESMO24 @OncoAlert https://t.co/MXZ9ASedfA |
|
Dr. Hope Rugo |
POSITIVE
|
Peter Schmid presents the OS data from KN522 #ESMO24 publl now in NEJM. >6 year FU: 9% EFS benefit, 5% ⬆️OS with pembro pre/post op for TNBC. Pts with PCR had 95% survival +/-pembro but 6% ⬆️OS in nonPCR + pembro. Safety same. Huge advance for TNBC. Need biomarkers! @OncoAlert https://t.co/DA02akjF0H |
|
Dr Amol Akhade |
POSITIVE
|
Excellent discussion 👏. Breast oncologist do it way way better than GU oncologist. 👍🙂 @drsarahsam @stolaney1 @ErikaHamilton9 @hoperugo @myESMO #ESM024 https://t.co/cLX9XwLyXy |
|
Timothée Olivier, MD |
POSITIVE
|
Great and balanced discussion by @lab_kok after the presentation of the KEYNOTE-522 overall survival results (peri-op pembro in early-TNBC) Many unanswered questions and important caveats were brought to attention. Refreshing!#ESMO2024 #ESMO24 https://t.co/ZxrlCYTNrQ |
|
Dr Amol Akhade |
NEUTRAL
|
Keynote 522 . Pembrolizumab in early stage TNBC shows OS benifit. We will love to see the OS data in with those with PCR and those who did not achieve PCR and Based Upon RCB . Remember the EFS benifit was maximum in RCB -2 and RCB -3 had infact detrimental EFS . @stolaney1… https://t.co/9VVkMwH95R https://t.co/394vj3UpKH |
|
Jacob Plieth |
NEUTRAL
|
Quite a turnaround since FDA initially greeted $MRK Keynote-522 filing (on pCR) with a CRL. Benefit likely driven by PD-L1+ves, but that's academic as Keytruda now has an all-comers label in this TNBC setting. https://t.co/BJV2but6T2 |
|
Matteo Lambertini, MD PhD |
NEUTRAL
|
Fully agree with super @lab_kok: more @myESMO annual congresses in #Barcelona !!! #ESMO24 #ESMOAmbassadors @OncoAlert @RebeccaDSing https://t.co/GcaHAg8l9V |
|
Dr. Hope Rugo |
NEUTRAL
|
Post KN522 critical to study who needs or does not need IO, optimal duration, and chemo options. Studies ongoing! @OncoAlert #ESMO24 @stolaney1 and many more. |
|
Abeid Athman (Omar). |
NEUTRAL
|
Marleen Kok with very thoughtful discussion on the design of the KN522, : do all patients need adjuvant pembrolizumab; the irAEA especially in young women who would like to get pregnant. #ESMO2024 @OncoAlert @myESMO @kevinpunie @matteolambe @PTarantinoMD https://t.co/bnHrPtY4RL https://t.co/hen6ZNlTbF |